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Abstract
This paper presents a DEA (Data Envelopment Analysis)/ Malmquist index method-
ology for measuring the R&D efficiency change of the Japanese pharmaceutical indus-
try. Letting each of ten firms in each year be a separate DMU (Decision-Making Unit)
and employing one input and three outputs in the DEA, and using the cumulative
frontier shift component on average proposed in the Malmquist index analysis, we
quite obviously show the industry-wide R&D efficiency change throughout the decade
1991-2000. The results empirically reveal that the R&D efficiency of the Japanese
industry has surely gotten worse almost monotonically for the decade at least as to
the pharmaceutical one.
Keywords: R&D efficiency change; Data envelopment analysis; Malmquist index;
Japanese pharmaceutical industry
1 Introduction
This paper measures R&D efficiency of Japanese pharmaceutical firms and examines how
R&D efficiency at the industry level has changed over time. R&D in firms, that can be
considered as a stage prior to production, would be as important as production. But
we have not quantitatively analyzed R&D efficiency so much as productivity. The lack
of how to measure R&D efficiency would be the main reason. In considering the input
and output of R&D, we cannot immediately specify what to be as the output, compared
with R&D investment as the input. Geisler (1995) and Brown and Svenson (1998) list
published articles, patents, new products, etc. as the output. That is, we cannot help
considering not a single output but multiple outputs of the R&D. This multiplicity of
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the output prevents from analyzing R&D efficiency by means of the ordinary production
function, i.e., parametric, approach.
Thus it is not easy to measure R&D efficiency, so that we have seldom observed its
chronological transition at the industry level. Has it gradually gotten better as incorpo-
rating some innovations into process like that productivity could be expected? For the
recent Japanese industry, it might not or might have even worsened (Sakakibara and Tsu-
jimoto, 2003). For also the pharmaceutical industry in the world, it is said that the R&D
efficiency is recently in decline (Tollman et al., 2004). After all, the recent change in R&D
efficiency has yet been elusive. Taking up the Japanese pharmaceutical industry, we verify
whether the R&D efficiency has gotten better or worse for the decade 1991-2000.
In order to analyze the R&D efficiency, we employ DEA (Data Envelopment Analysis)
(e.g., Charnes et al., 1994; Cooper et al., 2000). DEA is a non-parametric method that
can measure the relative efficiency, i.e., DEA efficiency, of objects called DMUs (Decision-
Making Units) with multiple inputs and multiple outputs. Although DEA could be applied
to various fields other than the standard efficiency analysis (e.g., Hashimoto and Ishikawa,
1993; Hashimoto, 1996), the DEA characteristic that can deal with even multiple outputs
has enabled to measure the efficiency of a novelty of DMU sets in also the original efficiency
analysis. For example, Nasierowski and Arcelus (2003) recently measure the efficiency of
45 national innovation systems with two inputs and three outputs using DEA. However,
we can find no DEA analyses of firms’ R&D efficiency except for Honjo and Haneda (1998).
They try to analyze the R&D efficiency of fourteen Japanese pharmaceutical firms with
one input and two outputs for the period 1977-1991. Refining their analyses, we also
preparatorily do DEA analyses using the panel data of ten pharmaceutical firms for 1991-
2000. But we should note that the ordinary DEA cannot analyze as taking the DEA
efficiency frontier shifting over time into consideration.
Then, we introduce DEA/ Malmquist index analysis (e.g., Fa¨re et al., 1994; Thanas-
soulis, 2001) to examine time series change in R&D efficiency at the industry level. The
Malmquist index can measure the ratio of DEA efficiencies in two different time periods
with shifting DEA efficiency frontiers. Although we recently have some DEA/ Malmquist
index applications, most of which are applied to productivity like Gonza´lez and Gasco´n
(2004). The Malmquist index can be decomposed into two components: “catch-up” and
“frontier shift”. While the former measures how much closer to the frontier a DMU, i.e., a
firm, moves, the latter does the movement of the frontier. Since the frontier is composed
of the “DEA efficient” DMUs among all the firms in a time period, the frontier shift means
the change at the industry level. Using this frontier shift, we devise to quite obviously
display the R&D efficiency change of the Japanese pharmaceutical industry throughout
the decade 1991-2000.
2 Data to measure R&D efficiency
To DEA-analyze R&D efficiency of the Japanese pharmaceutical firms as DMUs, we must
select inputs and outputs. DEA relatively evaluates how efficiently DMUs convert multiple
inputs into multiple outputs. That is, any DMU producing more outputs with fewer inputs
is judged relatively efficient. For the input, we straightforward employ R&D expenditure
(billion yen a year) as an indicator involving also the concept of number of researchers. For
the output, we propose the following three dimensions: We first list patents (the number
of patent applications publicly published in a year) as a proxy of invention, i.e., an indi-
cator directly reflecting the level of R&D outcomes. Next, we consider the other phases
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of outputs. R&D activities in firms can be divided into two: one aiming at “product
innovation” and the other aiming at “process innovation”. While the former contributes
sales increase through product discrimination, the latter does profit increase through cost
reduction (Odagiri, 1987). Corresponding to these phases respectively, we employ phar-
maceutical sales (ten billion yen a year) and operating profit (billion yen a year) as the
additional two outputs.
For these one input and three outputs, we initially provide four data panels as follows:
Each panel is ten firms × twenty years. That is, the sample period is the latest 1982-
2001 and the ten pharmaceutical firms are Takeda, Sankyo, Yamanouchi, Daiichi, Eisai,
Shionogi, Fujisawa, Chugai, Tanabe and Yoshitomi. They are all big enterprises driving
R&D and seem homogeneous as professional-medicine makers. Although we took the
biggest thirteen pharmaceutical firms of Japan into consideration at the beginning, Kyowa-
Hakko and Meiji-Seika were excluded because each firm’s medicine sales did not reach to
fifty percent of each whole sales. We also excluded Taisho because of its characteristic
as a popular-medicine maker peculiar vs the other firms. We collect annual data to the
one input and three outputs, for the ten firms in the period 1982-2001, from Data Book
(Tokyo: Japan Pharmaceutical Manufacturers Association) and NEEDS Database (Tokyo:
Nihon Keizai Shimbun, Inc.). The four indicators except for patents are all deflated to
the 2001 value.
In DEA-analyzing R&D efficiency in a year, it is not appropriate to apply the input
and output data of the same year. We should consider that variations in inputs would
cause observed variations in outputs of some years later. How many years would be the
time lag between the R&D expending and the realization of its outcomes? Science and
Technology Agency (1985) states that the average years of the lag would be 8.08 for the
Japanese pharmaceutical industry. Odagiri and Murakami (1992) estimate the lag six
to eight years. Based on these reports, we here employ eight years, i.e., we use input
data of a year together with output data of eight years later. However, this input-output
correspondence at intervals of eight years would not so strict, that we first compute three-
years moving averages being the middle year’s values for the four indicators in the period
1982-2001. Merging the moving-averaged input data for 1983-1992 in the moving-averaged
output data for 1991-2000, we reconstruct four data panels for the ten firms to analyze
R&D efficiency for the decade 1991-2000. For the time lag, we also tried seven and nine
years lag cases. It should be noted that the results of both cases had the same tendency
of the eight years lag case this paper adopts.
3 Preliminary DEA analyses of R&D efficiency
We preliminarily DEA-analyze the R&D efficiency of Japanese pharmaceutical firms us-
ing the panel data for the decade 1991-2000. The DEA model we employ is the CCR
(Charnes, Cooper and Rhodes) assuming the constant returns-to-scale. The CCR model
in its weak efficiency, input-oriented and envelopment form to measure DEA efficiency
(R&D efficiency) of target DMU j0, gj0(0 ≤ gj0 ≤ 1), is formulated as the following LP
(Linear Programming):








λjxj − θxj0 ≤ 0,
λj ≥ 0, j = 1, ..., n,
(θ unconstrained),
where θ, λj = decision variables to LP, n = the number of DMUs, yj = [y1j , ..., yrj , ..., ytj ]
= output vector of DMU j, yrj = the amount of output r from DMU j, t = the number of
outputs, xj = [x1j , ..., xij , ..., xmj ] = input vector of DMU j, xij = the amount of input i
to DMU j, m = the number of inputs. In our case, m = 1, input = (R&D expenditure),
and t = 3, output = (patents, pharmaceutical sales, operating profit). We can find DEA
efficiencies of all the DMUs by solving LP (1) n times, setting each DMU as target DMU
j0 in turn. Here, DMUs j0 with the minimum g∗j0 = 1 are judged DEA efficient, while the
other DMUs j0 with g∗j0 < 1 are DEA inefficient.
Three DEA analyses of the ten pharmaceutical firms for the decade 1991-2000 are
shown in Appendix. These analyses tell us the following: (1) Although Takeda and
Yoshitomi are respectively the largest and the smallest scaled firms measured by the
R&D expenditure, in Table A(1), both are judged DEA efficient in year 2000. This af-
firms the employment of CCR model assuming the constant returns-to-scale. (2) From
the results of Tables A(2)-(3), the R&D efficiency of Japanese pharmaceutical firms do
not seem to have gotten better for 1991-2000 at all. However, grasping exactly how the
R&D efficiency of the pharmaceutical industry has changed in this decade requires further
approaches beyond the ordinary DEA analyses.
4 Change in R&D efficiency for 1991-2000
To quantitatively show the R&D efficiency change of the industry for the decade 1991-
2000, we here introduce the DEA/ Malmquist index analysis and apply the same data
collected.
4.1 DEA/ Malmquist index analysis
DEA/Malmquist index analysis measures the Malmquist (productivity) index (Malmquist,
1953) in the DEA frame:
In Fig. 1, a single input and output DEA case, DMU j0 being evaluated was at point
A in period α and line OCD shows the CCR DEA efficiency frontier. Then, the input
oriented DEA efficiency of DMU j0 is measured by PC/PA (< 1, DEA inefficient). When
point A is on the frontier, the DEA efficiency is 1 (DEA efficient). Suppose that in period
β (β > α), DMU j0 has moved to point B and the frontier itself has also shifted to line
OEF. DEA efficiency change of DMU j0 can be measured by the ratio of DEA efficiency
in period β to that in period α, but the frontier has shifted, so that we compute the
geometric mean of ratios as to the two frontiers in periods α and β. This is the DEA
(CCR input oriented)/ Malmquist index of DMU j0 between periods α and β








Here, MI > 1 means gain in DEA efficiency of DMU j0 from period α to β, whileMI = 1
and MI < 1 mean the status quo and loss respectively.
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Transforming formula (2), Malmquist index can be decomposed into two components
as follows:























As each term in the right hand side of formula (3) shows, CU indicates Catch-Up index,
i.e, CU > 1 means that DMU j0 has moved closer to the period β frontier than to the
period α one. CU = 1 and CU < 1 mean that it has the same distance and that it has
moved farther, respectively. FS indicates Frontier Shift index, and FS > 1 means gain in
DEA efficiency frontier shift from period α to β measured from the location of DMU j0,
i.e., the frontier has moved so as to have the more output with the fewer input as shown
in Fig. 1. FS = 1 and FS < 1 mean no change and loss respectively.
Since PE/PA in Fig. 1 is, for example, the DEA efficiency of the period α DMU j0
measured by means of the period β frontier, we denote it as θ[Dα, F β]. Then from formula
(4),












In LP (1), letting xαj , y
α
j = xj , yj in period α respectively, θ[D
α, Fα] can be obtained as












j − θxαj0 ≤ 0,
λj ≥ 0, j, ..., n,
(θ unconstrained).
θ[Dβ, F β] can also be obtained by the LP (6) replaced α by β.












j − θxαj0 ≤ 0,
λj ≥ 0, j, ..., n,
(θ unconstrained),
this forms the DEA exclusion model (Andersen and Petersen, 1993). Finally, we can obtain
θ[Dβ, Fα] by also the DEA exclusion model (7) exchanged α and β.
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4.2 Cumulative Malmquist index
Applying the data to LPs (6) and (7), and through formula (5), we can compute the
catch-up CUj0 [α, β], the frontier shift FSj0 [α, β] and the Malmquist MIj0 [α, β] indices.
These indices for a year are usually compared to the preceding year, i.e., α = β - 1.
However, such annually successive indices do not seem appropriate to see the chronological
change throughout the sample period in the wide range of vision. Therefore, we propose to
employ another index than the successive one. Tables 1-3 respectively showMIj0 [1991, β],
CUj0 [1991, β] and FSj0 [1991, β], β = 1991, ..., 2000. They are all compared to the start
year 1991. Since they involve their successive changes from the start year up to year β, we
call them cumulative indices. Fa¨re et al. [1994] and Coelli et al. [1998] use the sequential
product of the annually successive indices to demonstrate the cumulated change. But, as
the former authors state, the Malmquist index as well as the frontier shift one do not satisfy
the circular test: e.g., MIj0 [α, α + 1] × MIj0 [α + 1, α + 2] 6= MIj0 [α, α + 2]. Therefore,
we adopt the cumulative indices above instead of the sequential products. The cumulative
index values when β = 1991 could be 1. Further, the MI, CU and FS indices themselves
are also multiplicative, so that we employ geometric means, not arithmetic ones, as all the
averages here.
The Malmquist index indicates the R&D efficiency change of a firm taking the R&D
efficiency frontier shifting into consideration. We here note that the R&D efficiency frontier
of a year is composed of the most efficient, i.e., DEA efficient, firms in R&D of the year.
Thus Table 1 shows that the R&D efficiency of Japanese pharmaceutical firms has gotten
worse in average at the annual rate 7.4% for the decade 1991-2000, and has in year 2000
dropped to fifty percent of the start year 1991. This implies a big loss in firms’ R&D
efficiency. We should note that all the ten firms have this decreasing R&D efficiency. The
most worsened for this decade would be Tanabe while the least, Takeda.
The catch-up measures how much closer to the yearly R&D efficiency frontier a firm
moves. For only the catch-up, six firms out of the ten except for Yamanouchi, Shionogi,
Fujisawa and Tanabe have never gotten worse for this decade (Table 2). The cumulative
catch-up is the ratio of R&D efficiency of a firm in year β to that in the start year 1991.
Therefore, in Table A(1), the cross-section DEA efficiency of a year divided by that of
year 1991 is the catch-up value of the year in Table 2. That is, for both Yamanouchi and
Yoshitomi, the values in Tables 2 and A(1) are equal, and for Sankyo, for example, the
values in Table 2 do not exceed 1/0.96 = 1.040, i.e., its upper limit.
Picking up rows from Tables 1-3, we can draw a graph of the three cumulative indices
for each firm. Fig. 2 for Sankyo and Fig. 3 for Takeda are examples: In Fig. 2, the
catch-up shows that Sankyo has been on the R&D efficiency frontier on and after year
1993. Therefore, the Malmquist has moved as synchronized with the frontier shift, and has
in year 2000 gone worsened to 57.4% of the start year, which has been due to the frontier
shift backward. For Takeda (Fig. 3), as is mentioned before, the catch-up has gotten
better since the start year and it has reached to the upper limit, i.e., Takeda has ridden
onto the frontier, in year 2000. The cumulative Malmquist indices are also over 1 for
1992-1994, so that the R&D efficiency of Takeda had improved for this period compared
to the start year. In this way, we can quantitatively show the chronological changes in a
firm’s R&D efficiency using the three cumulative indices.
4.3 R&D efficiency loss by the industry and innovative firms
The cumulative frontier shift index indicates the move of the industry’s R&D efficiency
frontier from the viewpoint (location) of each firm. Therefore, the frontier shift on average
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(Table 3) could be an appropriate indicator to measure the R&D efficiency change at
the industry level. The annual change rate 0.927 means that the R&D efficiency of the
Japanese pharmaceutical industry has worsened at the annual rate 7.3% for 1991-2000.
That is, the great R&D efficiency frontier shift backward, reverse to as shown in Fig. 1,
has occurred between years 1991 and 2000.
Fig. 4 is a graph of the cumulative frontier shift on average in Table 3. It shows that
the R&D efficiency of the industry has gotten worse to under 70% of the start year 1991
in year 1995, the end of the first half, and has finally dropped to 50.6% in year 2000.
Although there is observed the recovery in year 1998, we must say that the industry’s
R&D efficiency has almost monotonically been decreasing throughout the decade. Thus,
we could quite obviously show how the industry-wide R&D efficiency has changed, which
implies the great loss in R&D efficiency by the Japanese pharmaceutical industry for the
decade 1991-2000.
For the decade with the R&D efficiency frontier almost annually shifted backward,
what firms have made the frontier shift onward even temporarily? As such innovative
firms, we designate DMUs j0 in year β that satisfy the following conditions (Fa¨re et al.,
1994):
a) FSj0 [β − 1, β] > 1; b) θ[Dβ, F β] = 1; c) θ[Dβ, F β−1] > 1.
That is, those DMUs exist on the frontier judged “shifted onward from the preceding year”
(conditions a and b) except for existing on the backward part in the crossed-frontiers case
(condition c). Amongst the cross-section DEA efficient DMUs in Table A(1), which satisfy
condition b), only three DMUs, Sankyo 1996, 1997 and 1998, satisfy also conditions a) and
c). Therefore, we here note that Sankyo in the period 1996-1998 has been the innovative
firm of the decade.
5 Summary and conclusions
This paper presented a DEA/ Malmquist index methodology for measuring the R&D
efficiency change at the industry level. Using the cumulative frontier shift index proposed
in the methodology, we could quantitatively show the time series change in the R&D
efficiency of the Japanese pharmaceutical industry throughout the decade 1991-2000. We
here found the great R&D efficiency loss by the industry for the decade and that the
industry’s R&D efficiency had dropped in year 2000 to fifty percent of the start year 1991,
though several innovators had existed.
Why have the firms continued to spend money on the R&D despite that the R&D
efficiency has not improved? It is considered that some factors beyond the efficiency might
drive the R&D expenditure. Haneda and Odagiri (1998) indicate that R&D investment
affects the value of firm. That is, firms might find another meaning of R&D expenditure
than R&D itself. To examine this would require further studies. Anyhow, we could
empirically reveal that the R&D efficiency of the Japanese pharmaceutical industry, whose
change had seemed elusive, had surely been in decline for the decade 1991-2000.
Appendix
Solving DEA model (1) with one input and three outputs, we obtain DEA efficiencies
g∗j0 shown in Table A. In this Table, value 1 indicates DEA efficient. Table A(1) shows
the results of ten DEA cross-section analyses with ten DMUs (n = 10 firms), i.e., the
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cross-section DEA by year, treating each firm as a separate DMU. For example, in year
1996, both Sankyo and Fujisawa are the most efficient firms in R&D, while Yoshitomi has
only 52% efficiency of these two best firms in the year. We find that Sankyo would have
been most efficient in R&D because it is judged DEA efficient in eight years among the
decade. On the contrary, half of the ten firms have never been DEA efficient throughout
the decade.
Table A(2) shows the results of ten DEA time series analyses with ten DMUs (n =
10 years), i.e., the time series DEA (Cooper et al., 1995; Hashimoto and Kodama, 1997)
by firm, treating each year as a separate DMU. For Shionogi, for example, 1991 and 1993
are its most efficiency years in R&D, while in year 2000, its R&D efficiency drops to
63% of these two best years of the firm. We find that 1991, the first year of the decade,
is necessarily listed as the most efficient years in R&D to every firm. And only three
firms, Takeda, Sankyo and Yoshitomi, have such years in also the last half of the decade,
1996-2000. Table A(3) shows the results of a DEA panel analysis with 100 DMUs (n
= 100 = 10 firms × 10 years), i.e., the panel DEA treating each firm in each year as a
separate DMU. We find that the efficiency frontier in this DEA is composed of only two
DMUs, Yamanouchi 1991 and Yoshitomi 1991. These are the most efficient DMUs in R&D
among the 100 and both are in the first year of the decade. Further, the average of DEA
efficiencies of all the 50 DMUs in the first half of the decade, 1991-1995, is 0.68 as against
0.47 in the last half.
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Table 1
Cumulative Malmquist index MI j0 [1991, β], β = 1991, …, 2000
Firm Year β Annual
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 change
rate
Takeda 1.000 1.065 1.000 1.003 0.874 0.858 0.818 0.832 0.811 0.906 0.989
Sankyo 1.000 0.949 0.897 0.815 0.778 0.787 0.845 0.842 0.695 0.574 0.940
Yamanouchi 1.000 0.920 0.834 0.758 0.705 0.653 0.535 0.486 0.454 0.465 0.918
Daiichi 1.000 0.943 0.848 0.760 0.657 0.606 0.548 0.543 0.517 0.516 0.929
Eisai 1.000 0.909 0.861 0.835 0.794 0.669 0.561 0.577 0.567 0.558 0.937
Shionogi 1.000 0.919 0.864 0.768 0.722 0.647 0.602 0.549 0.511 0.490 0.924
Fujisawa 1.000 0.895 0.870 0.898 0.793 0.645 0.465 0.459 0.394 0.366 0.894
Chugai 1.000 1.005 0.944 0.846 0.825 0.689 0.690 0.602 0.559 0.552 0.936
Tanabe 1.000 0.920 0.854 0.739 0.587 0.507 0.421 0.398 0.363 0.359 0.893
Yoshitomi 1.000 0.878 0.701 0.636 0.404 0.282 0.338 0.406 0.423 0.415 0.907
Average 1.000 0.939 0.864 0.800 0.699 0.612 0.562 0.552 0.514 0.502 0.926
Table 2
Cumulative catch-up index CU j0 [1991, β], β = 1991, …, 2000
Firm Year β Annual
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 change
rate
Takeda 1.000 1.182 1.275 1.387 1.332 1.479 1.461 1.330 1.316 1.543 1.049
Sankyo 1.000 1.000 1.040 1.040 1.040 1.040 1.040 1.040 1.040 1.040 1.004
Yamanouchi 1.000 1.000 1.000 1.000 1.000 0.996 0.796 0.696 0.739 0.870 0.985
Daiichi 1.000 1.025 0.998 0.984 0.919 0.917 0.827 0.826 0.927 1.011 1.001
Eisai 1.000 0.983 1.023 1.126 1.177 1.058 0.861 0.879 1.031 1.076 1.008
Shionogi 1.000 0.961 0.984 0.964 0.969 0.956 0.876 0.835 0.918 0.921 0.991
Fujisawa 1.000 1.002 1.165 1.243 1.243 1.243 0.959 0.899 0.899 0.900 0.988
Chugai 1.000 1.065 1.081 1.102 1.188 1.072 1.108 0.931 0.998 1.047 1.005
Tanabe 1.000 1.018 1.072 1.001 0.851 0.787 0.661 0.613 0.662 0.710 0.963
Yoshitomi 1.000 1.000 1.000 0.984 0.678 0.522 0.655 0.774 0.954 1.000 1.000
Average 1.000 1.022 1.061 1.076 1.022 0.975 0.900 0.864 0.934 0.994 0.999
 The upper limit for each firm.  See Table A(1).
Table 3
Cumulative frontier shift index FS j0 [1991, β], β = 1991, …, 2000
Firm Year β Annual
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 change
rate
Takeda 1.000 0.901 0.784 0.723 0.656 0.580 0.560 0.626 0.616 0.587 0.943
Sankyo 1.000 0.949 0.863 0.784 0.748 0.756 0.812 0.809 0.668 0.551 0.936
Yamanouchi 1.000 0.920 0.834 0.758 0.705 0.656 0.673 0.698 0.614 0.534 0.933
Daiichi 1.000 0.920 0.849 0.773 0.715 0.661 0.663 0.658 0.557 0.510 0.928
Eisai 1.000 0.924 0.841 0.741 0.675 0.632 0.651 0.656 0.550 0.518 0.930
Shionogi 1.000 0.956 0.877 0.797 0.745 0.677 0.687 0.658 0.557 0.532 0.932
Fujisawa 1.000 0.893 0.747 0.722 0.638 0.519 0.484 0.511 0.438 0.407 0.905
Chugai 1.000 0.943 0.873 0.768 0.694 0.643 0.623 0.646 0.560 0.527 0.931
Tanabe 1.000 0.904 0.796 0.738 0.689 0.644 0.637 0.650 0.548 0.506 0.927
Yoshitomi 1.000 0.878 0.701 0.647 0.596 0.541 0.515 0.524 0.444 0.415 0.907
Average 1.000 0.919 0.815 0.744 0.685 0.627 0.624 0.639 0.551 0.506 0.927
Table A
DEA efficiencies
(1) Cross-section DEA by year
Firm Year
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Takeda 0.65 0.77 0.83 0.90 0.86 0.96 0.95 0.86 0.85 1
Sankyo 0.96 0.96 1 1 1 1 1 1 1 1
Yamanouchi 1 1 1 1 1 1.00 0.80 0.70 0.74 0.87
Daiichi 0.88 0.90 0.88 0.86 0.81 0.81 0.73 0.73 0.81 0.89
Eisai 0.58 0.57 0.59 0.65 0.68 0.61 0.50 0.51 0.59 0.62
Shionogi 0.57 0.55 0.57 0.55 0.56 0.55 0.50 0.48 0.53 0.53
Fujisawa 0.80 0.81 0.94 1 1 1 0.77 0.72 0.72 0.72
Chugai 0.63 0.67 0.68 0.69 0.74 0.67 0.69 0.58 0.62 0.66
Tanabe 0.81 0.82 0.87 0.81 0.69 0.64 0.53 0.50 0.54 0.57
Yoshitomi 1 1 1 0.98 0.68 0.52 0.66 0.77 0.95 1
(2) Time series DEA by firm
Firm Year
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Takeda 1 1 0.97 0.97 0.87 0.86 0.85 0.90 0.91 1
Sankyo 1 1 0.98 0.88 0.86 0.90 1.00 1 0.82 0.67
Yamanouchi 1 0.96 0.88 0.80 0.75 0.67 0.57 0.52 0.50 0.50
Daiichi 1 0.95 0.88 0.81 0.75 0.68 0.62 0.61 0.62 0.62
Eisai 1 0.95 0.96 0.91 0.88 0.83 0.75 0.67 0.72 0.81
Shionogi 1 0.99 1 0.93 0.89 0.74 0.70 0.67 0.68 0.63
Fujisawa 1 0.95 1 1 0.99 0.83 0.80 0.72 0.63 0.56
Chugai 1 1 1 0.93 0.93 0.74 0.74 0.72 0.80 0.77
Tanabe 1 0.94 0.89 0.75 0.67 0.67 0.68 0.67 0.77 0.93
Yoshitomi 1 0.98 0.93 0.95 0.86 0.80 0.85 0.96 1 1
(3) Panel DEA
Firm Year
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Takeda 0.65 0.69 0.64 0.64 0.56 0.55 0.53 0.56 0.64 0.74
Sankyo 0.96 0.92 0.88 0.80 0.79 0.85 0.98 1.00 0.80 0.59
Yamanouchi 1 0.96 0.88 0.80 0.75 0.67 0.57 0.52 0.50 0.50
Daiichi 0.88 0.83 0.77 0.69 0.60 0.55 0.50 0.48 0.45 0.45
Eisai 0.58 0.53 0.52 0.48 0.46 0.39 0.34 0.33 0.32 0.33
Shionogi 0.57 0.53 0.50 0.44 0.41 0.37 0.35 0.32 0.29 0.28
Fujisawa 0.80 0.72 0.70 0.72 0.64 0.53 0.40 0.39 0.34 0.32
Chugai 0.63 0.62 0.59 0.52 0.50 0.41 0.39 0.37 0.35 0.34
Tanabe 0.81 0.74 0.69 0.60 0.49 0.43 0.37 0.33 0.30 0.30














Fig.1. DEA efficiency change with the frontier shifting over time.
































































Fig. 4.  R&D efficiency loss by the industry for 1991-2000.
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